Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q6HA08

UPID:
ASTL_HUMAN

ALTERNATIVE NAMES:
Oocyte astacin; Ovastacin; ZP2-proteinase

ALTERNATIVE UPACC:
Q6HA08; Q3KNT0

BACKGROUND:
The protein Astacin-like metalloendopeptidase, with alternative names Oocyte astacin and Ovastacin, is integral to the process of fertilization. It ensures proper sperm-egg interaction and blocks additional sperm from binding to the zona pellucida after fertilization, a key step in preventing polyspermy.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in fertilization and its association with the fertility disorder Oocyte/zygote/embryo maturation arrest 11, Astacin-like metalloendopeptidase represents a promising target for developing treatments aimed at enhancing reproductive technologies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.